TerminatedNot Applicable

QuiremSpheres Observational Study

Stopped: did not meet planned recruitment expectations with a slow recruitment rate

Germany, Netherlands20 participantsStarted 2018-06-21

Plain-language summary

The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with diagnosis of primary liver tumor or metastases in the liver from other primary cancers, allocated to SIRT with QuiremSpheres® as decided by a multidisciplinary tumor board * Patient is ≥ 18 years * Patient has understood and signed written informed consent to data collection in the study Exclusion Criteria: * Patient's refusal * Local practice guidelines prohibiting the patient to receive SIRT

What they're measuring

Tumor response

Timeframe: 3 months

Safety

Timeframe: 12 months

Trial details

NCT IDNCT03563274

SponsorTerumo Europe N.V.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-07-31

View on ClinicalTrials.gov More Liver, Cancer of, Non-Resectable trials